MARKET

BAYRY

BAYRY

Bayer Aktien
OTCPK

Real-time Quotes | Nasdaq Last Sale

13.34
+0.09
+0.68%
Closed 15:57 08/10 EDT
OPEN
13.40
PREV CLOSE
13.25
HIGH
13.42
LOW
13.30
VOLUME
179.18K
TURNOVER
2.39M
52 WEEK HIGH
18.45
52 WEEK LOW
12.45
MARKET CAP
52.42B
P/E (TTM)
11.83
1D
5D
1M
3M
1Y
5Y
FDA Approves Expanded Use For Bayer's Prostate Cancer Drug
Benzinga · 3d ago
Hutchmed fruquintinib improves survival, meets main goal of colorectal cancer study
Hutchmed (China) (NASDAQ:HCM) <a href="https://seekingalpha.com...
Seekingalpha · 3d ago
Bayer's Nubeqa gets FDA approval for expanded use in prostate cancer subtype
The U.S. Food and Drug Administration approved the expanded use of Bayer's (<a href="https://seekingalpha.c...
Seekingalpha · 3d ago
BRIEF-FDA Approves Darolutamide Tablets For Metastatic Hormone-Sensitive Prostate Cancer
BRIEF-FDA Approves Darolutamide Tablets For Metastatic Hormone-Sensitive Prostate Cancer
Reuters · 5d ago
Bayer (BAYRY) Earnings & Revenues Surpass Estimates in Q2
Bayer (BAYRY) beats estimates for both earnings and revenues in the second quarter of 2022.
Zacks · 6d ago
Bayer says arbitration ruling over BASF claims is imminent
Bayer's chief executive said an arbitration court would soon decide on claims brought by rival BASF, saying it overpaid for assets that Bayer sold to secure antitrust clearance for the takeover of Monsanto. Bayer CEO Werner Baumann told analysts in a call...
Reuters · 6d ago
The Big Ag Short: Let's Not Hedge Our Bets Against Our Global Food System
On February 24, 2022, Vladimir Putin began his unlawful invasion of Ukraine – a war he had denied he would enter into just hours before. Today, five weeks later, he is continuing his atrocities des...
News Direct · 6d ago
Bayer lifts forecasts as food shortages boost demand for seeds and weedkiller
Bayer has upgraded its 2022 growth and profit forecasts, capitalising on the sharp rise in food prices that has boosted demand for seeds and weedkiller. The sharp increase in global food prices in the wake of Russia’s invasion of Ukraine has been a boon f...
Financial Times · 08/04 10:39
More
No Data
Learn about the latest financial forecast of BAYRY. Analyze the recent business situations of Bayer Aktien through EPS, BVPS, FPS, and other data. This information may help you make smarter investment decisions.
Analyst Rating

Based on 1 analysts

Strong Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

100.00%Strong Buy
0.00%Buy
0.00%Hold
0.00%Under-perform
0.00%Sell
Analyst Price Target
The average BAYRY stock price target is 21.63 with a high estimate of 21.63 and a low estimate of 21.63.
High21.63
Average21.63
Low21.63
Current 13.34
EPS
Actual
Estimate
0.250.500.740.99
Q3 2021
Q4 2021
Q1 2022
Q2 2022
Q3 2022
Institutional Holdings
Institutions: 40
Institutional Holdings: 4.67M
% Owned: 0.12%
Shares Outstanding: 3.93B
TypeInstitutionsShares
Increased
7
161.06K
New
6
843.05K
Decreased
14
931.46K
Sold Out
8
425.27K
  • Performance
  • Asset Allocation
  • Dividend History
No Data
Industry
Pharmaceuticals
+0.30%
Pharmaceuticals & Medical Research
+0.92%
Key Executives
Chairman - Supervisory/Director
Norbert Winkeljohann
Chairman - Management/Chief Executive Officer
Werner Baumann
Vice Chairman - Supervisory/Independent Director
Oliver Zuehlke
Chief Financial Officer/Management Board
Wolfgang Nickl
Management Board
Sarena Lin
Management Board
Stefan Oelrich
Management Board
Heiko Schipper
Independent Director/Supervisory Board
Simone Bagel-Trah
Independent Director/Supervisory Board
Horst Baier
Independent Director/Supervisory Board
Norbert Bischofberger
Independent Director/Supervisory Board
Ertharin Cousin
Independent Director/Supervisory Board
Thomas Elsner
Independent Director/Supervisory Board
Colleen Goggins
Independent Director/Supervisory Board
Robert Gundlach
Independent Director/Supervisory Board
Heike Hausfeld
Independent Director/Supervisory Board
Reiner Hoffmann
Independent Director/Supervisory Board
Fei-Fei Li
Independent Director/Supervisory Board
Frank Loellgen
Independent Director/Supervisory Board
Petra Reinbold-Knape
Independent Director/Supervisory Board
Michael Schmidt-Kiessling
Independent Director/Supervisory Board
Andre van Broich
Independent Director/Supervisory Board
Alberto Weisser
Independent Director/Supervisory Board
Otmar Wiestler
Supervisory Board
Paul Achleitner
Supervisory Board
Andrea Sacher
No Data
No Data
About BAYRY
Bayer AG is a German-based life science company. The Company's segments are Pharmaceuticals, Consumer Health, Crop Science and Animal Health. The Pharmaceuticals segment focuses on researching, developing and marketing prescription products and specialty therapeutics especially in the areas of cardiology, oncology, gynecology, hematology and ophthalmology, as well as radiopharmacology and others. The company is focusing on their oncology platform o Targeted Alpha Therapies for treating prostate cancer. Th Consumer Health segment develops, produces and markets nonprescription over-the-counter products in the dermatology, dietary supplement, analgesic, gastrointestinal, cold, allergy, sinus and flu, foot care and sun protection categories, among others. The Crop Science segment researches, develops and markets crop protection solutions and seeds, and includes the subsidiary Monsanto. The Animal Health segment is engaged in the development, production and marketing of prescription and non

Webull offers kinds of Bayer AG (ADR) stock information, including OTCPK:BAYRY real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, BAYRY stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading BAYRY stock methods without spending real money on the virtual paper trading platform.